Therapy and diagnosis of diseases associated with human endogenous retrovirus expression
GeNeuro SA
Incorporated
01.02.2006Headquarters
Plan-les-OuatesSupport
The therapeutic substances from GeNeuro fight illnesses such as multiple sclerosis right at their roots. They prevent the processes that eventually lead to brain damage and invalidity. The first substances are already in the clinical phase and are being tested on healthy volunteers.
www.geneuro.com
Sectors
News
Federal government signs four contracts for the development of COVID-19 medicines (startupticker.ch)
GeNeuro raises EUR 6M private placement to support its preclinical research and development of treatments for neurodegenerative diseases for Post-COVID patients (venturelab.swiss)
GeNeuro raises 6 million euros in a private placement (startupticker.ch)
GeNeuro closes €17.5 million private placement (startupticker.ch)
GeNeuro: 12-month-results underpinning hope (startupticker.ch)
GeNeuro To Receive ?12 Million Milestone Payment (startupticker.ch)
Eclosion: Incubator for market stars in Geneva (startupticker.ch)
GeNeuro’s IPO raised a total of €33 million (startupticker.ch)
GeNeuro plans IPO on Euronext Paris (startupticker.ch)
Servier invests in GeNeuro (startupticker.ch)
GeNeuro and Servier Sign $450M Agreement to Develop Multiple Sclerosis Treatment (startupticker.ch)
Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis (startupticker.ch)
US$ 700'000 for Swiss Biotech-Company (startupticker.ch)
GeNeuro Successfully Completes Phase 2a Clinical Study (startupticker.ch)
Geneuro starts Phase IIa clinical study (startupticker.ch)
GeNeuro?s first drug candidate completes phase I clinical study (startupticker.ch)